David Woodhouse is the founder of NGM Bio Holdings. NGM Bio Holdings has raised $257M in total funding. Latest round: Series A.
David Woodhouse is the CEO of NGM Biopharmaceuticals (formerly NGM Bio Holdings), a biopharmaceutical company focused on developing therapies for liver and metabolic diseases. He previously served as CEO of Nuvig Therapeutics before his appointment at NGM. Under his leadership, NGM Bio executed a strategic pivot in 2024, cutting 75% of staff and halting its mid-stage liver disease program to focus on other assets.
Full founder directory · Investor directory · Company funding database · Fundraising library